Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.19.3.a.u2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets    
Cash and cash equivalents $ 173,016 $ 9,811
Accounts receivable, net 94,242 76,919
Inventories 14,405 8,650
Prepaid assets 6,327 7,727
Other current assets 2,748 561
Total current assets 290,738 103,668
Property and equipment (net of accumulated depreciation of $68,809 and $50,127, respectively) 64,188 60,888
Operating lease right-of-use assets 26,492  
Intangible assets, net 126,640 140,029
Goodwill 198,601 197,892
Other assets 2,847 2,538
Total assets 709,506 505,015
Current liabilities    
Accounts payable 19,568 17,779
Accrued compensation 21,365 19,062
Accrued expenses and other liabilities 7,548 8,986
Short-term portion of financing obligations 5,432 6,298
Short-term portion of operating lease liabilities 3,381  
Short-term portion of term loan 5,000 7,873
Current pharma contract liabilities 1,610 927
Total current liabilities 63,904 60,925
Long-term liabilities    
Long-term portion of financing obligations 3,199 5,250
Long-term portion of operating lease liabilities 24,034  
Long-term portion of term loan, net 91,829 87,880
Revolving credit facility, net 0 5,000
Other long-term liabilities 3,566 3,060
Deferred income tax liability, net 15,566 22,457
Total long-term liabilities 138,194 123,647
Total liabilities 202,098 184,572
Commitments and Contingencies 0 0
Stockholders’ equity    
Common stock, $0.001 par value, (250,000,000 shares authorized; 104,781,236 and 94,465,440 shares issued and outstanding, respectively) 105 94
Additional paid-in capital 520,278 340,291
Accumulated other comprehensive loss (1,618) (579)
Accumulated deficit (11,357) (19,363)
Total stockholders’ equity 507,408 320,443
Total liabilities and stockholders’ equity $ 709,506 $ 505,015